Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Rena R. Wing,Wei Lang,Thomas A. Wadden,Monika M. Safford,William C. Knowler,Alain G. Bertoni,James O. Hill,Frederick L. Brancati,Anne L. Peters,Lynne E. Wagenknecht +9 more
Reads0
Chats0
TLDR
Modest weight losses of 5 to <10% were associated with significant improvements in CVD risk factors at 1 year, but larger weight losses had greater benefits.Abstract:
OBJECTIVE Overweight and obese individuals are encouraged to lose 5–10% of their body weight to improve cardiovascular disease (CVD) risk, but data supporting this recommendation are limited, particularly for individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS We conducted an observational analysis of participants in the Look AHEAD (Action For Health in Diabetes) study ( n = 5,145, 40.5% male, 37% from ethnic/racial minorities) and examined the association between the magnitude of weight loss and changes in CVD risk factors at 1 year and the odds of meeting predefined criteria for clinically significant improvements in risk factors in individuals with type 2 diabetes. RESULTS The magnitude of weight loss at 1 year was strongly ( P P = 0.79). Compared with weight-stable participants, those who lost 5 to 1c (odds ratio 3.52 [95% CI 2.81–4.40]), a 5-mmHg decrease in diastolic blood pressure (1.48 [1.20–1.82]), a 5-mmHg decrease in systolic blood pressure (1.56 [1.27–1.91]), a 5 mg/dL increase in HDL cholesterol (1.69 [1.37–2.07]), and a 40 mg/dL decrease in triglycerides (2.20 [1.71–2.83]). The odds of clinically significant improvements in most risk factors were even greater in those who lost 10–15% of their body weight. CONCLUSIONS Modest weight losses of 5 toread more
Citations
More filters
Journal ArticleDOI
Community-based behavioral weight-loss treatment: long-term maintenance of weight loss, physiological, and psychological outcomes.
TL;DR: A community-based treatment program may be an effective form of behavioral-weight-loss treatment for overweight/obese adults and weight losses, along with physiological and psychological benefits, were sustained over time.
Journal ArticleDOI
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial
Li Zang,Yu Liu,Jianlin Geng,Yong Luo,Fang Bian,Xiaofeng Lv,Jialin Yang,Jun Liu,Yongde Peng,Yukun Li,Yue Sun,Heidrun Bosch-Traberg,Yiming Mu +12 more
TL;DR: To compare the efficacy and safety of liraglutide versus sitagliptin as add‐on to metformin after 26 weeks of treatment in Chinese patients with type 2 diabetes mellitus (T2DM).
Journal ArticleDOI
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation.
Francisco Lopez-Jimenez,Wael Almahmeed,Harold E. Bays,Ada Cuevas,Emanuele Di Angelantonio,Carel W. le Roux,Naveed Sattar,Marie Chan Sun,Gary A. Wittert,Fausto J. Pinto,John P.H. Wilding +10 more
TL;DR: This position paper, developed by the WOF and the WHF, aims to improve understanding of the direct and indirect links between overweight/obesity and CVD, the key controversies in this area and evidence relating to cardiometric outcomes with available weight management options.
Journal ArticleDOI
Binge Eating and Weight Loss Outcomes in Individuals with Type 2 Diabetes: 4‐Year Results from the Look AHEAD Study
Ariana M. Chao,Thomas A. Wadden,Amy A Gorin,Jena Shaw Tronieri,Rebecca L. Pearl,Zayna M. Bakizada,Susan Z. Yanovski,Robert I. Berkowitz,Robert I. Berkowitz +8 more
TL;DR: Whether an intensive lifestyle intervention for weight reduction precipitates binge eating (BE) and whether BE attenuates 4‐year weight loss among participants with type 2 diabetes and overweight or obesity is assessed.
Journal ArticleDOI
Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis
TL;DR: Available evidence from randomized controlled trials suggests that SGLT2 inhibitor monotherapy exerts more beneficial effects on weight reduction than both metformin and dipeptidyl peptidase 4 inhibitors.
References
More filters
Journal ArticleDOI
Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
TL;DR: A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
Journal Article
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults : the evidence report
Journal ArticleDOI
Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
TL;DR: A prospective, controlled Swedish Obese Subjects Study involved obese subjects who underwent gastric surgery and contemporaneously matched, conventionally treated obese control subjects, which reported follow-up data for subjects who had been enrolled for at least 2 years or 10 years before the analysis.
Journal ArticleDOI
Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Frank M. Sacks,George A. Bray,Vincent J. Carey,Steven R. Smith,Donna H. Ryan,Stephen D. Anton,Katherine McManus,Catherine M. Champagne,Louise M. Bishop,Nancy Laranjo,Meryl S. LeBoff,Jennifer Rood,Lilian de Jonge,Frank L. Greenway,Catherine M. Loria,Eva Obarzanek,Donald A. Williamson +16 more
TL;DR: Low-calorie diets result in clinically meaningful weight loss regardless of which macronutrients they emphasize, and improved lipid-related risk factors and fasting insulin levels.
Journal ArticleDOI
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-Year Results of the Look AHEAD Trial
Mark A. Espeland,Xavier Pi-Sunyer,George L. Blackburn,Frederick L. Brancati,George A. Bray,Renee Bright,Jeanne M. Clark,Jeffrey M. Curtis,John P. Foreyt,Kathryn Graves,Steven M. Haffner,Barbara Harrison,James O. Hill,Edward S. Horton,John M. Jakicic,Robert W. Jeffery,Karen C. Johnson,Steven E. Kahn,David E. Kelley,Abbas E. Kitabchi,William C. Knowler,Cora E. Lewis,Barbara J. Maschak-Carey,Brenda Montgomery,David M. Nathan,Jennifer Patricio,Anne L. Peters,J. Bruce Redmon,Rebecca S. Reeves,Donna H. Ryan,Monika M. Safford,Brent Van Dorsten,Thomas A. Wadden,Lynne E. Wagenknecht,Jacqueline Wesche-Thobaben,Rena R. Wing,Susan Z. Yanovski +36 more
TL;DR: At 1 year, ILI resulted in clinically significant weight loss in people with type 2 diabetes and was associated with improved diabetes control and CVD risk factors and reduced medicine use in ILI versus DSE.
Related Papers (5)
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
Michael D. Jensen,Donna H. Ryan,Caroline M. Apovian,Jamy D. Ard,Anthony G. Comuzzie,Karen A. Donato,Frank B. Hu,Van S. Hubbard,John M. Jakicic,Robert F. Kushner,Catherine M. Loria,Barbara E. Millen,Cathy Nonas,F. Xavier Pi-Sunyer,June Stevens,Victor J. Stevens,Thomas A. Wadden,Bruce M. Wolfe,Susan Z. Yanovski +18 more